



## Division of Medical Services Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437  
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



**AGENDA**  
**ARKANSAS MEDICAID DUR BOARD QUARTERLY DRUG UPDATE**  
**July 17, 2019, 9:00 A.M. – 12:00 P.M.**  
**LOCATION OF MEETING IS DEPARTMENT OF HUMAN SERVICES OFFICE**  
**700 Main Street**  
**Donaghey Plaza South Conference Room B**  
**Little Rock, AR 72201**

\*\*\*\*PLEASE NOTE THE NEW MEETING LOCATION\*\*\*\*

\*\*\*ARRIVE EARLIER THAN NORMAL TO ALLOW TIME FOR CHECK-IN\*\*\*

**I. OUTSIDE SPEAKERS**

*DUR Board Bylaws, Section 7.02, allow **Outside speakers** at the meeting-- Outside speakers may request to speak on a topic that is posted on the upcoming DUR Board meeting agenda. **Speakers must submit the request in writing to the Chair of the DUR Board to speak at the meeting on a specific topic.** All speakers are required to **submit an emailed copy** of the public comments to the Chair of the DUR Board that he/she will present the day of the meeting. The public comments must be received by the Chair of the DUR Board **at least 2 weeks prior to the DUR Board meeting date.** Public comments at the DUR Board meeting are **limited to a total comment time of five (5) minutes per drug.** If there is more than one speaker for the same drug, the speakers must **split the total comment time of five (5) minutes on that drug.***

**II. UNFINISHED / OLD BUSINESS AND GENERAL ORDERS / AND PROPOSALS TO REVISE PREVIOUS CRITERIA**

- A. ANNOUNCEMENTS
- B. APPROVAL OF THE MINUTES FROM THE PREVIOUS MEETING.
- C. UPDATE ON SYSTEM EDITS, IMPLEMENTATIONS, OR FOLLOW-UP ITEMS.
  - 1) Follow-up items from April 17, 2019 DUR Board Quarterly Drug Update: None
  - 2) Implementation information from April 17, 2019 DUR Board Quarterly Drug Update and May 8, 2019 Preferred Drug List (PDL) Drug Review Update
  - 3) Review proposed changes to bylaws
  - 4) Update on opioid usage
  - 5) Medication Assisted Treatment forms
- D. PROPOSED CHANGES TO EXISTING CRITERIA and EDITS, INCLUDING POINT OF SALE (POS) CRITERIA, MANUAL REVIEW PA CRITERIA, OR CLAIM EDITS:
  - 1) EMFLAZA
  - 2) PROTON PUMP INHIBITORS REVIEW
  - 3) OSTEOPOSIOSIS TREATMENT REVIEW

**III. NEW BUSINESS**

- A. PROPOSED NEW CLINICAL POINT OF SALE CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS
  - None
- B. MANUAL REVIEW PROPOSED CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
  - 1) NUZYRA
  - 2) ABILIFY MYCITE
  - 3) FIRDAPSE
  - 4) BLINCYTO
  - 5) BALVERSA
  - 6) ALPHA1-PROTEINASE INHIBITORS
  - 7) HCV treatment for pediatrics
  - 8) TIBSOVO
  - 9) VYNDAQEL AND VYNDAMAX
  - 10) TARCEVA
- C. PROPOSED NEW CLAIM EDITS (QUANTITY, DAILY DOSE, ACCUMULATION, GENDER, AGE):
  - None
- D. ProDUR Report UPDATE
- E. RDUR Report UPDATE

[humanservices.arkansas.gov](http://humanservices.arkansas.gov)

Protecting the vulnerable, fostering independence and promoting better health